ergoferon
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
4
Earliest trial started Feb 1, 2011 (NCT01804946)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Interferon alphaImmunity, passive
Interferon alpha immunity, passive
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ergoferon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05069649 | Phase 3 | Oct 6, 2021 | Materia Medica Holding |
| NCT03039621 | Phase 4 | Oct 1, 2016 | Materia Medica Holding |
| NCT03039699 | Phase 4 | Jun 1, 2016 | Materia Medica Holding |
| NCT01850446 | Phase 4 | May 1, 2013 | Materia Medica Holding |
| NCT01843842 | Phase 3 | Apr 1, 2013 | Materia Medica Holding |
| NCT01765920 | Phase 3 | Dec 1, 2012 | Materia Medica Holding |
| NCT01804946 | Phase 4 | Feb 1, 2011 | Materia Medica Holding |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Materia Medica Holding | For profit | 7 | 7 | 2 | 2011 |
1 organizations
Page 1 / 1